American healthcare spend makes up 20% of the US GDP, and our system still leaves nearly everyone who engages deeply dissatisfied if not with the outcome then at least with the process. Ever since our first investment as a firm into Maven Clinic in 2016, Company Ventures has been keenly aware of the scale of opportunity to disrupt and improve the way healthcare is executed and experienced in the US. We’ve since invested across: 

• New insurance models (Centivo) 

• Mental health (Octave) 

• Drug adherence (Hero) 

• Data interoperability (Particle) 

• Food-as-medicine (Season) 

• Infant nutrition (Nara) 

• Fertility (Oova; Juniper) 

• New employer healthcare models (Eden) 

• Family care clinics (Juno)

• Flexible medical staffing enablement (Nomad) 

...and more.

As thrilled as we are by the performance of our healthcare portfolio, we think we’ve only scratched the surface of the potential embedded in working with exceptional founder talent to reinvent US healthcare. And it’s for this reason that we couldn’t be more excited to welcome Mark Rosenblum to our team as Company Ventures’ newest investment partner to lead our healthcare investing going forward.  

Mark is an operator and investor with experience spanning early stage incubation, public market investing, and investment banking. Prior to joining Company Ventures, Mark was a Managing Director at Redesign Health, where he helped incubate early stage companies including digital oncology platform Jasper Health and mental healthcare company Uplift. He also worked as a public market investor at Epoch Investment Partners, and in equity research and investment banking roles at Morgan Stanley and Jefferies.

Mark earned his MBA at the Fuqua School of Business at Duke University and a BS in Finance at University of Maryland. We’re thrilled to welcome Mark to the Company Ventures team and to expand our investment team.